Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. - Wikidata - wikimedia - TriplyDB

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

http://www.wikidata.org/entity/Q43263384

about

The gut hormones in appetite regulation The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.Emerging treatment options for short bowel syndrome: potential role of teduglutide Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice Effect of glucagon-like peptide 2 on hepatic, renal, and intestinal disposition of 1-chloro-2,4-dinitrobenzene Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Microbial translocation across the GI tract Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.The "cryptic" mechanism of action of glucagon-like peptide-2.Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.Review article: a comparison of glucagon-like peptides 1 and 2.The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.Teduglutide in Crohn's disease.Systemic immune activation in HIV and potential therapeutic options.Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease.Integrated Neural and Endocrine Control of Gastrointestinal Function.Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn's disease: preliminary report.Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats.Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.The gut as a sensory organ.Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey.Glucagon like peptide-2 and neoplasia; a systematic review.Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model.The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D.

P2860

Q21296779-21F3621A-2E25-4051-8EEA-71A1754482B5 Q26745700-5CAB4D74-985B-4C2B-BE08-9A6FF882EAE5 Q26752511-47844BED-50B6-43D9-97B7-93519013A7A2 Q34494154-441607CD-6124-43F3-808C-5A90C6F3F65B Q35046115-B881AF87-B24B-474D-AD54-B190E83577F1 Q35304614-903CF4EC-24C1-4331-952D-ECE1D36C1957 Q35429613-DFB269DA-6AC5-480B-BF0C-D768339595F9 Q35986076-34882272-E711-4349-BE51-EE7AFBDE172C Q36057404-E5251395-37E2-4C22-9AE5-1FF35430B2E2 Q36063090-805E1F13-5843-4382-A0EB-B9802B3E222A Q36171894-F69456BD-F865-4BBF-AE0A-EF0BD8C9D872 Q36309586-68059F01-CC5D-4DF7-91E7-D4F88C7038F2 Q36441742-9C46346E-9009-44DD-BFA1-4D0ED1939F3B Q36710034-1AB8CAEF-B245-4903-8A14-7C9CAA9C2E6A Q37247764-DED2CE2D-AED1-4143-8BEA-5FEEB1025838 Q37840099-98999E31-EA91-408F-A5BC-E44D937BDF63 Q37870031-852DE174-9265-43F4-9446-BC445ADB44CA Q37975414-10080CEB-00EF-4E17-BC76-C6EA19DA33C5 Q38048602-64C3429A-0B14-48DE-9202-322D51CD7841 Q38057350-2F46A4D8-3E37-4E74-B1FC-1E029A93FDD4 Q38101129-A599B4FA-5794-47F2-BD0D-808445749385 Q38120028-7EBF9910-4EE5-4D4E-A4F2-AA24788A138C Q38189500-6D42B47E-3CEB-487D-A81A-D3CCCA09A208 Q38542147-FC1D4979-58AA-4BE0-B488-31FA151F5505 Q38886433-83D3244C-D665-4DA1-A3B3-B2452C0E0582 Q39585744-1A5E4D31-BDAE-4AB8-BC8A-5230D092DA60 Q39739606-C8639740-590C-4967-836A-8A9A34FD59F8 Q42721362-FE64748B-17A9-42B2-9834-2371410F646B Q42943394-11C974C6-B99D-4F94-9702-22CBEB52832B Q43168687-168E8C11-24FC-4063-92BE-99F84EC06893 Q45216920-267A647D-E932-438B-9F67-88C2DC50A6BB Q45894561-80B326C3-BB01-464F-A872-D82D0AD5DE03 Q46938538-FD3D3269-1717-477F-BD98-8C958DCC973F Q49901206-A9219A2F-A476-474A-AC8F-F430D2307412 Q51830867-BC53B3BA-2AEA-4DAC-8C34-023AABB1201A Q53283425-BEF140F8-8351-4229-A174-1ED23E214FF7

P2860

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

http://www.wikidata.org/entity/Q43263384

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@en

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@nl

type

label

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@en

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@nl

prefLabel

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@en

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@nl

P1433

Q43263384-754AB3BE-3F31-4F41-87A2-0E66D0BE36E3

P1476

Q43263384-4996F20E-8E74-4CC2-A301-E4BCDACFD9BB

P2093

Q43263384-5CF3D389-B57A-4E0A-8D1A-35660A9FA046

Q43263384-695656F4-FA4A-4E0C-A6BD-1742DA2E9638

Q43263384-C7815FD9-7CC8-4862-B9B7-DA81BD5FF9C5

Q43263384-CE53B0B1-5B7E-4890-BC72-F0726089C76E

Q43263384-ECEBE226-9F08-4E95-B5D7-9B8029231A25

Q43263384-F293581B-A18E-4662-8445-5F777E2FAD9F

P2860

Q43263384-07716439-C4D2-4A1B-BBA6-64BA1D394DFE

Q43263384-1B844223-9075-4E56-8D1E-2EC5F4E9E9EC

Q43263384-1CD48C4D-0D8A-492C-8050-559B1A3283CC

Q43263384-1D6D2DEF-32FD-4F83-8620-B68D5E648D01

Q43263384-25E938E4-39C2-4CE7-A132-F53E4880294D

Q43263384-2671A0F4-B2BF-4F5C-BB3F-ECBD27FC5863

Q43263384-293E46F0-2960-438F-83D8-010268F5AA38

Q43263384-354EEE54-3716-493F-B701-0D65235C26E9

Q43263384-3859EDA2-36CA-437C-A879-580401516AF2

Q43263384-39466538-5599-4755-BDE5-23B44C355556

P304

Q43263384-EAD45025-4B81-4E57-B610-BCE8F0319144

P31

Q43263384-387F2D47-03E4-4AEB-9466-ED6984FFB340

P356

Q43263384-C3CDC4E7-7A5C-4B5A-A920-3467E21D726A

P433

Q43263384-32A76A6F-836E-4A69-A3F1-FBE4F840592D

P478

Q43263384-0700B8C9-7445-48C1-9EA4-BA16A9C62A10

P577

Q43263384-EB7F5D37-A413-4DC0-8AD5-32DE7BDDB63A

P5875

Q43263384-29D5F61E-58A6-4A73-B7CD-0363D7CA1233

P698

Q43263384-C43BDC5B-DA86-4FAA-9176-D27F95266391

P921

Q43263384-5A5298CF-6048-494B-B323-7CB480F908BC

P356

P1433

Inflammatory Bowel Diseases

P1476

Teduglutide, a novel mucosally ...... ate to severe Crohn's disease.

@en

P2093

Alan L Buchman

http://www.w3.org/2001/XMLSchema#string

Charles N Bernstein

http://www.w3.org/2001/XMLSchema#string

John C Fang

http://www.w3.org/2001/XMLSchema#string

Seymour Katz

http://www.w3.org/2001/XMLSchema#string

Souheil G Abou-Assi

http://www.w3.org/2001/XMLSchema#string

Teduglutide Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse

Certolizumab pegol for the treatment of Crohn's disease

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa

Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans.

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.

P304

962-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.21117

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26887252

http://www.w3.org/2001/XMLSchema#string

P698

19821509

http://www.w3.org/2001/XMLSchema#string

P921